secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2026-06-03T20:07:02+00:00
Accession:  0001628280-26-040225
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys prices $150M common stock offering at $26.50/sh; proceeds to fund royalty repurchase
--------------------------------------------------------------------------------

- 5,660,378 shares at $26.50/share; gross proceeds ~$150M, net ~$142.5M.
- Proceeds to partially fund $200M upfront payment to repurchase royalty obligation from Tanabe Pharma.
- Offering expected to close June 4, 2026; joint book-runners: BofA, Goldman Sachs, Evercore ISI.
- Company separately announced a $500M committed debt facility with Pharmakon Advisors.
- Underwriters purchased at $25.3075/share; shelf registration effective on filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/0001628280-26-040225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/mlys-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-040225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer